Hormonal effects of CV 205–502, a novel octahydrobenzo [g] quinoline with potent dopamine agonist properties
- 1 January 1988
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 43 (17) , 1355-1362
- https://doi.org/10.1016/0024-3205(88)90301-3
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205–502Brain Research, 1988
- DISCORDANT RESPONSES OF PROLACTINOMA TO TWO DIFFERENT DOPAMINE AGONISTSClinical Endocrinology, 1986
- EFFECT OF LOW‐DOSE DOPAMINE INFUSION ON BASAL AND STIMULATED TSH AND PROLACTIN CONCENTRATIONS IN MANClinical Endocrinology, 1985
- COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIAClinical Endocrinology, 1985
- Octahydrobenzo[g]quinolines: potent dopamine agonists which show the relationship between ergolines and apomorphineJournal of Medicinal Chemistry, 1985
- Prolactinomas.BMJ, 1985
- The effect of Low-Dose Dopamine Infusion on Anterior Pituitary Hormone Secretion in Normal Female SubjectsClinical Science, 1984
- Drugs Five Years LaterAnnals of Internal Medicine, 1984
- DOPAMINE AND T.S.H. SECRETION IN MANThe Lancet, 1977